Nonsteroidal anti-inflammatory drugs may prevent colon cancer through suppression of hepatocyte growth factor expression

Eur J Pharmacol. 1999 Feb 12;367(1):131-8. doi: 10.1016/s0014-2999(98)00943-1.

Abstract

Nonsteroidal anti-inflammatory drugs which inhibit cyclooxygenase have been reported to suppress colon carcinogenesis. However the mechanism has not yet been elucidated. Growth factors such as hepatocyte growth factor, which are produced by fibroblasts, have been shown to be important in carcinogenesis and the progression of various human cancers. In the present study, we tested the hypothesis that nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor expression through an endogenous prostaglandin-mediated pathway in cultured human colonic fibroblasts. Human colonic fibroblasts were obtained from a resected colon and cultured. Hepatocyte growth factor and prostaglandin E2 were measured by enzyme-linked immunosorbent assay. Induction of cyclooxygenase-1 and cyclooxygenase-2 protein was estimated by immunoblotting. Prostaglandins increased hepatocyte growth factor production significantly in a dose- and time-dependent manner. Cholera toxin and 8-bromo cAMP also stimulated hepatocyte growth factor production. Further, prostaglandin E1 significantly increased cellular cAMP. The prostaglandin EP2 and EP4 receptors were detected by reverse transcription-polymerase chain reaction. Interleukin-1beta dramatically increased prostaglandin E2 production and significantly stimulated hepatocyte growth factor synthesis. Interleukin-1beta induced cyclooxygenase-2 but not cyclooxygenase-1 protein. Indomethacin significantly reduced interleukin-1beta-induced prostaglandin E2 release and hepatocyte growth factor production. These results suggest that prostaglandin is a factor for the production of hepatocyte growth factor by human colonic fibroblasts. Nonsteroidal anti-inflammatory drugs may suppress colon carcinogenesis, in part, through the suppression of hepatocyte growth factor expression by inhibiting endogenous prostaglandin production.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alprostadil / pharmacology
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Cell Survival / drug effects
  • Cells, Cultured
  • Cholera Toxin / pharmacology
  • Colon / cytology
  • Colon / drug effects
  • Colon / metabolism
  • Colonic Neoplasms / metabolism
  • Colonic Neoplasms / prevention & control*
  • Cyclic AMP / metabolism
  • Cyclic AMP / pharmacology
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • Dinoprostone / biosynthesis
  • Fibroblasts / cytology
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism
  • Gene Expression / drug effects
  • Hepatocyte Growth Factor / biosynthesis*
  • Humans
  • Indomethacin / pharmacology
  • Interleukin-1 / pharmacology
  • Isoenzymes / biosynthesis
  • Isoenzymes / drug effects
  • Membrane Proteins
  • Mucous Membrane / cytology
  • Mucous Membrane / drug effects
  • Mucous Membrane / metabolism
  • Prostaglandin-Endoperoxide Synthases / biosynthesis
  • Prostaglandin-Endoperoxide Synthases / drug effects
  • Prostaglandins / pharmacology
  • RNA, Messenger / drug effects
  • RNA, Messenger / metabolism
  • Receptors, Prostaglandin E / genetics
  • Receptors, Prostaglandin E, EP2 Subtype
  • Receptors, Prostaglandin E, EP4 Subtype

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Interleukin-1
  • Isoenzymes
  • Membrane Proteins
  • PTGER2 protein, human
  • PTGER4 protein, human
  • Prostaglandins
  • RNA, Messenger
  • Receptors, Prostaglandin E
  • Receptors, Prostaglandin E, EP2 Subtype
  • Receptors, Prostaglandin E, EP4 Subtype
  • Hepatocyte Growth Factor
  • Cholera Toxin
  • Cyclic AMP
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • PTGS1 protein, human
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Alprostadil
  • Dinoprostone
  • Indomethacin